• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY:BMY)

    59.77 +0.22 (+0.37%)
    Streaming Delayed Price Updated: 10:22 AM EDT, May 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bristol-Myers Squibb

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    89 90 Next >
    News headline image
    Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
    The market appears to be short-sighted. 
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    1 Profitable Stock to Keep an Eye On and 2 We Brush Off
    Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
    Via StockStory
    Topics Energy
    News headline image
    Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio ↗
    Via Chartmill
    Topics Earnings
    News headline image
    3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations ↗
    These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them. 
    Via The Motley Fool
    News headline image
    10 Years Later: 5 Winners in a Thinking World ↗
    What happens when you actually do the thing most investors only talk about and hold stocks for a full decade? 
    Via The Motley Fool
    News headline image
    2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
    Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
    Via StockStory
    News headline image
    Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
    Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin... 
    Via StockStory
    Topics Stocks
    News headline image
    Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
    This may be an excellent deal for those focused on the long game. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗
    Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,... 
    Via MarketBeat
    News headline image
    Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product... 
    Via StockStory
    Topics Earnings
    News headline image
    Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged... 
    Via StockStory
    News headline image
    Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill... 
    Via StockStory
    News headline image
    Why Bristol Myers Squibb Stock Rocked the Market Today ↗
    It scored crushing beats on both revenue and profitability in its first quarter. 
    Via The Motley Fool
    News headline image
    Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗
    Bristol Myers (BMY) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill... 
    Via StockStory
    News headline image
    Bristol Myers Squibb Reports First Quarter Financial Results for 2026
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri... 
    Via StockStory
    News headline image
    3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
    It may not seem like it at first, but these dividends are safe. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
    This pharma stock is cheap for a reason. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Bristol Myers Squibb: Low Volatility Meets High Dividend Yield ↗
    Volatility and dividend yield are important metrics for investors thinking about a long-term buy. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
    As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields. 
    Via The Motley Fool
    Topics Intellectual Property World Trade
    News headline image
    1 Unpopular Stock That Should Get More Attention and 2 We Question
    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
    Via StockStory
    News headline image
    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
    From Ardelyx, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    89 90 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.